Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)’s share price traded down 1.4% on Friday . The stock traded as low as $11.54 and last traded at $12.07, with a volume of 303,586 shares traded. The stock had previously closed at $12.24.

Several equities analysts recently weighed in on the company. Canaccord Genuity reiterated a “buy” rating and set a $22.00 target price on shares of Aquinox Pharmaceuticals in a research report on Wednesday, August 17th. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Jefferies Group increased their target price on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research report on Friday, August 5th. Finally, Needham & Company LLC assumed coverage on Aquinox Pharmaceuticals in a research report on Thursday, May 12th. They set a “buy” rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Aquinox Pharmaceuticals presently has an average rating of “Buy” and an average price target of $19.86.

The stock’s market capitalization is $208.95 million. The company has a 50 day moving average of $8.99 and a 200 day moving average of $8.42.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.22. Equities research analysts anticipate that Aquinox Pharmaceuticals Inc. will post ($2.08) EPS for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.